3 transcripts
AORT
Earnings call transcript
NYSE
2024 Q1
6 May 24
that the On-X aortic valve has an even more durable safety and efficacy profile for patients receiving low-dose warfarin than predicted by the results
AORT
Earnings call transcript
NYSE
2023 Q4
15 Feb 24
efficacy and safety endpoints, demonstrating a statistically significant reduction in all-cause mortality and the primary endpoint of major adverse events
AORT
Earnings call transcript
NYSE
2023 Q2
3 Aug 23
centers in approximately 100 patients who have experienced acute type A aortic dissection. The combined primary efficacy and safety endpoints of the trial
- Prev
- 1
- Next